The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery.
The global DNA methylation market size was valued at US$ 1.9 Bn in 2025 and is projected to reach US$ 7.7 Bn by 2036, growing ...
AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of ...
The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...
The Manila Times on MSN
Artificial intelligence seen as a force multiplier for research, discovery
ARTIFICIAL intelligence is no longer just a peripheral tool in research. The rapid accumulation, availability and ...
How AI, robotics, and modular design are transforming single-cell and spatial biology into scalable, precision-driven engines of discovery.
The market for microbiome sample preparation technology presents opportunities driven by demand for personalized medicine, ...
Looking to usher in a more “predictable” year in 2026, Illumina is working with officials in China as it remains on the ...
Discover GRAIL’s MCED screening tests, Illumina’s divestiture impact, and an $8B valuation base with TAM upside tied to FDA ...
The San Diego firm took a step in that direction on Tuesday, when it unveiled what it says will be the world’s largest dataset of its kind, the Billion Cell Atlas. The atlas is based on the results of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results